Visualization analysis of research hotspots and development trends of hyperkalemia in hemodialysis patients_West China Medical Journal

Authors：

ZHU Lin ¹ , ZHENG Haotian ¹ , WAN Zhenghong ¹ , HE Li ¹ ,  ZHOU Li ²

1. Hemodialysis Department of Nephrology, West China Hospital, Sichuan University / West China School of Nursing, Sichuan University, Chengdu, Sichuan 610041, P. R. China;
2. Hemodialysis Department of Nephrology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

ZHOU Li, Email: 446125447@qq.com

Keywords：

Hemodialysis; hyperkalemia; research hotspots; visualization analysis

DOI：

10.7507/1002-0179.202406163

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To analyze the research hotspots and trends in the field of hyperkalemia in hemodialysis patients at home and abroad, and to provide reference for the research and prevention and control of hyperkalemia in hemodialysis patients. Methods China National Knowledge Infrastructure (CNKI) and Web of Science databases were searched by computer for literature about the hyperkalemia in hemodialysis patients published between January 1995 and January 2023. The included literature was analyzed using visualization analysis tools for visualization, including high-frequency keywords, keyword co-occurrence map, keyword emergence intensity and keyword time series prediction. Results A total of 10 275 articles were included. Among them, there were 10 036 articles from web of science and 239 articles from CNKI. The number of articles in this research field showed a trend of steady increase year by year. The United States was in a leading position in the research and development in this field, followed by China. At the same time, the research in this field presents the characteristics of multidisciplinary integration. The development trends of research hotspots in the next 5 years were risk and health education research. Conclusions The number of research articles related to hyperkalemia in hemodialysis patients is gradually increasing. Multidisciplinary approach and integration is a research hotspot and frontier in the development of hyperkalemia in hemodialysis patients both domestically and internationally.

Citation： ZHU Lin, ZHENG Haotian, WAN Zhenghong, HE Li, ZHOU Li. Visualization analysis of research hotspots and development trends of hyperkalemia in hemodialysis patients. West China Medical Journal, 2024, 39(8): 1259-1264. doi: 10.7507/1002-0179.202406163 Copy

1.	叶倩呈, 王三营, 刘倩影, 等. 维持性血液透析患者自体动静脉内瘘失功风险预测模型的研究进展. 中国护理管理, 2022, 22(7): 1102-1105.
2.	罗培艺, 马良, 苟慎菊. 合并危险因素的高钾血症诊治进展. 中国全科医学, 2022, 25(36): 4587-4594.
3.	黄耀禹, 毛慧娟, 邢昌赢. 维持性血液透析患者的高钾血症管理进展. 中国血液净化, 2021, 20(12): 793-796.
4.	Levey AS, Eckardt KU, Dorman NM, et al. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. Kidney Int, 2020, 97(6): 1117-1129.
5.	孙静, 杜玄一. 慢性肾脏病高钾血症发病机制及治疗进展. 实用临床医药杂志, 2021, 25(5): 125-128.
6.	中华医学会肾脏病分会专家组. 中国慢性肾脏病患者血钾管理实践专家共识. 中华肾脏病杂志, 2020, 36(10): 781-792.
7.	郑法雷, 章友康, 陈香美, 等. 慢性肾脏病——公共卫生领域的新挑战——写在 2009“世界肾脏日”之前. 北京医学, 2009, 31(3): 129-130.
8.	周国民, 李建民. 从“温阳法”论治慢性肾功能衰竭高钾血症. 中华中医药杂志, 2020, 35(6): 2939-2942.
9.	王冲, 李月红. 维持性血液透析患者血钾波动的危害及干预策略. 肾脏病与透析肾移植杂志, 2020, 29(4): 386-389, 368.
10.	高玉梅, 吴桃峰, 林丽华, 等. 风险评估工具在血液透析患者高钾血症分级管理中的应用. 中国血液净化, 2022, 21(9): 692-696.
11.	Clase CM, Carrero JJ, Ellison DH, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int, 2020, 97(1): 42-61.
12.	Ding X, Yang Z. Knowledge mapping of platform research: a visual analysis using VOSviewer and CiteSpace. Electron Commer Res, 2022, 22(3): 787-809.
13.	郭富蒸, 张丽颖, 于皓南, 等. 早复极综合征的再认识. 中国老年学杂志, 2018, 38(4): 1007-1010.
14.	蒋建平, 谭佳英, 雷炎, 等. 血液透析抢救高钾血症所致恶性心律失常临床分析. 临床心血管病杂志, 2010, 26(3): 229.
15.	Neuen BL, Oshima M, Agarwal R, et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation, 2022, 145(19): 1460-1470.
16.	Momoniat T, Ilyas D, Bhandari S. ACE inhibitors and ARBs: managing potassium and renal function. Cleve Clin J Med, 2019, 86(9): 601-607.
17.	Wen Y, Xia Y, Gong Y. Effects and safety of sacubitril/valsartan (SV) on heart function and blood pressure in maintenance hemodialysis (MHD) patients. Am J Transl Res, 2022, 14(5): 3439-3447.
18.	Kosiborod M, Cherney D, Desai AS, et al. Design of Phase Ⅳ, double-blind, placebo-controlled, randomized-withdrawal trial evaluating sodium zirconium cyclosilicate for the management of hyperkalemia in patients with symptomatic heart failure with reduced ejection fraction (REALIZE-K Trial). Circ, 2021, 144(Suppl 1): A8895.
19.	Fishbane S, Charytan DM, Chertow GM, et al. Consensus-based recommendations for the management of hyperkalemia in the hemodialysis setting. J Ren Nutr, 2022, 32(4): e1-e14.
20.	Crespo-Leiro MG, Barge-Caballero E, Segovia-Cubero J, et al. Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA heart failure long-term registry. Revista española de cardiología (English ed. ), 2020, 73(4): 313-323.
21.	Sumida K, Lau WL, Kovesdy CP, et al. Microbiome modulation as a novel therapeutic approach in chronic kidney disease. Curr Opin Nephrol Hypertens, 2021, 30(1): 75-84.
22.	Kaze AD, Zhuo M, Kim SC, et al. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol, 2022, 21(1): 47.
23.	刘卫华, 林紫宁, 洪富源. 血液透析并发心力衰竭的防治新进展. 中国实用内科杂志, 2021, 41(11): 917-921.
24.	Yang A, Singh B, Lavin PT, et al. Placebo effect in clinical studies in hyperkalemia: a double-blind, randomized, placebo-controlled phase 3 study of sodium zirconium cyclosilicate (ZS-9). Am J Kidney Dis, 2015, 65(4): A91.
25.	董建华, 王绪臻, 范文静, 等. 环硅酸锆钠治疗维持性血液透析患者慢性高钾血症的疗效. 肾脏病与透析肾移植杂志, 2022, 31(1): 15-20.
26.	张洁婷, 梁玉婷, 魏爽, 等. 血液透析患者透析相关知识知晓情况及其影响因素分析. 中国血液净化, 2019, 18(11): 791-794.
27.	王婷婷, 马迎春. 维持性血液透析患者运动康复的实施及影响因素. 中国血液净化, 2019, 18(3): 204-206.
28.	胡瑞, 邱文龙, 赵喜红, 等. 从肾移植术后感染新冠肺炎谈免疫宿主低下人群的管理. 中华危重病急救医学, 2022, 34(5): 492-496.
29.	Bhatt GC, Sethi SK, Mehta I, et al. Literature review of the efficacy of high-volume hemofiltration in critically ill pediatric patients. Blood Purif, 2022, 51(8): 649-659.
30.	Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med, 2014, 370(15): 1383-1392.
31.	Choi JY, Cho SG, Jang KS, et al. Voriconazole-induced Severe Hyperkalemia Precipitated by Multiple Drug Interactions. Electrolyte Blood Press, 2020, 18(1): 10-15.
32.	Dos Santos RG, Malinovski J, Scatone N, et al. MO595 frequency of intake of dietary fiber sources not associated with hyperkalemia in hemodialys patients in a multicenter study. Nephrol Dial Transpl, 2021, 36(Suppl 1): gfab089-008.
33.	姜美. 研究尿毒症患者输血发生高钾血症原因及护理. 中国现代药物应用, 2017, 11(16): 166-167.
34.	李萍, 钱巧慧, 崔丽, 等. 医联体内知识共享的范畴研究. 中国全科医学, 2018, 21(13): 1539-1545.
35.	Rossignol P, Pitt B. Heart failure and chronic kidney disease patients. J Am Coll Cardiol, 2021, 78(4): 344-347.
36.	刘宏, 刘必成. 慢性肾脏病合并高钾血症: 老问题、新对策. 中华医学杂志, 2021, 101(42): 3447-3450.
37.	Gaudry S, Quenot JP, Hertig A, et al. Timing of renal replacement therapy for severe acute kidney injury in critically ill patients. Am J Respir Crit Care Med, 2019, 199(9): 1066-1075.
38.	Chen H, Cheng Q, Wang J, et al. Long‐term efficacy and safety of hypoxia‐inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: a meta‐analysis including 13, 146 patients. J Clin Pharm Ther, 2021, 46(4): 999-1009.
39.	Brueske B, Sidhu MS, Schulman‐Marcus J, et al. Hyperkalemia is associated with increased mortality among unselected cardiac intensive care unit patients. J Am Heart Assoc, 2019, 8(7): e011814.
40.	Thongprayoon C, Cheungpasitporn W, Radhakrishnan Y, et al. Association of serum potassium derangements with mortality among patients requiring continuous renal replacement therapy. Ther Apher Dial, 2022, 26(6): 1098-1105.
41.	陈洪, 周春华. 2007 年北京市新入血液透析患者病因组成分析. 中国血液净化, 2009, 8(10): 567-570.
42.	Lisi F, Grande D, Parisi G, et al. Hyperkalemia is the main cause of mineralocorticoid receptor antagonists withdrawal and is associate with a worse prognosis in patients with chronic heart failure. Eur Heart J Suppl, 2019, 21(E): E230-E231.
43.	Lowe KM, Cruz JB, Jones KM. Complications in patients with chronic kidney disease. Crit Care Nurs Clin North Am, 2022, 34(4): 395-407.
44.	Stevens JS, Hastie JM, Spellman J, et al. Optimizing perioperative renal replacement therapy for patients undergoing cardiac surgical procedures requiring cardiopulmonary bypass. Blood Purif, 2022: 1-7.
45.	Conley R, Rich RL, Montero J. Safety of a nurse-driven standardized potassium replacement protocol in critically ill patients with renal insufficiency. Crit Care Nurse, 2021, 41(2): e10-e16.

1. 叶倩呈, 王三营, 刘倩影, 等. 维持性血液透析患者自体动静脉内瘘失功风险预测模型的研究进展. 中国护理管理, 2022, 22(7): 1102-1105.
2. 罗培艺, 马良, 苟慎菊. 合并危险因素的高钾血症诊治进展. 中国全科医学, 2022, 25(36): 4587-4594.
3. 黄耀禹, 毛慧娟, 邢昌赢. 维持性血液透析患者的高钾血症管理进展. 中国血液净化, 2021, 20(12): 793-796.
4. Levey AS, Eckardt KU, Dorman NM, et al. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. Kidney Int, 2020, 97(6): 1117-1129.
5. 孙静, 杜玄一. 慢性肾脏病高钾血症发病机制及治疗进展. 实用临床医药杂志, 2021, 25(5): 125-128.
6. 中华医学会肾脏病分会专家组. 中国慢性肾脏病患者血钾管理实践专家共识. 中华肾脏病杂志, 2020, 36(10): 781-792.
7. 郑法雷, 章友康, 陈香美, 等. 慢性肾脏病——公共卫生领域的新挑战——写在 2009“世界肾脏日”之前. 北京医学, 2009, 31(3): 129-130.
8. 周国民, 李建民. 从“温阳法”论治慢性肾功能衰竭高钾血症. 中华中医药杂志, 2020, 35(6): 2939-2942.
9. 王冲, 李月红. 维持性血液透析患者血钾波动的危害及干预策略. 肾脏病与透析肾移植杂志, 2020, 29(4): 386-389, 368.
10. 高玉梅, 吴桃峰, 林丽华, 等. 风险评估工具在血液透析患者高钾血症分级管理中的应用. 中国血液净化, 2022, 21(9): 692-696.
11. Clase CM, Carrero JJ, Ellison DH, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int, 2020, 97(1): 42-61.
12. Ding X, Yang Z. Knowledge mapping of platform research: a visual analysis using VOSviewer and CiteSpace. Electron Commer Res, 2022, 22(3): 787-809.
13. 郭富蒸, 张丽颖, 于皓南, 等. 早复极综合征的再认识. 中国老年学杂志, 2018, 38(4): 1007-1010.
14. 蒋建平, 谭佳英, 雷炎, 等. 血液透析抢救高钾血症所致恶性心律失常临床分析. 临床心血管病杂志, 2010, 26(3): 229.
15. Neuen BL, Oshima M, Agarwal R, et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation, 2022, 145(19): 1460-1470.
16. Momoniat T, Ilyas D, Bhandari S. ACE inhibitors and ARBs: managing potassium and renal function. Cleve Clin J Med, 2019, 86(9): 601-607.
17. Wen Y, Xia Y, Gong Y. Effects and safety of sacubitril/valsartan (SV) on heart function and blood pressure in maintenance hemodialysis (MHD) patients. Am J Transl Res, 2022, 14(5): 3439-3447.
18. Kosiborod M, Cherney D, Desai AS, et al. Design of Phase Ⅳ, double-blind, placebo-controlled, randomized-withdrawal trial evaluating sodium zirconium cyclosilicate for the management of hyperkalemia in patients with symptomatic heart failure with reduced ejection fraction (REALIZE-K Trial). Circ, 2021, 144(Suppl 1): A8895.
19. Fishbane S, Charytan DM, Chertow GM, et al. Consensus-based recommendations for the management of hyperkalemia in the hemodialysis setting. J Ren Nutr, 2022, 32(4): e1-e14.
20. Crespo-Leiro MG, Barge-Caballero E, Segovia-Cubero J, et al. Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA heart failure long-term registry. Revista española de cardiología (English ed. ), 2020, 73(4): 313-323.
21. Sumida K, Lau WL, Kovesdy CP, et al. Microbiome modulation as a novel therapeutic approach in chronic kidney disease. Curr Opin Nephrol Hypertens, 2021, 30(1): 75-84.
22. Kaze AD, Zhuo M, Kim SC, et al. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol, 2022, 21(1): 47.
23. 刘卫华, 林紫宁, 洪富源. 血液透析并发心力衰竭的防治新进展. 中国实用内科杂志, 2021, 41(11): 917-921.
24. Yang A, Singh B, Lavin PT, et al. Placebo effect in clinical studies in hyperkalemia: a double-blind, randomized, placebo-controlled phase 3 study of sodium zirconium cyclosilicate (ZS-9). Am J Kidney Dis, 2015, 65(4): A91.
25. 董建华, 王绪臻, 范文静, 等. 环硅酸锆钠治疗维持性血液透析患者慢性高钾血症的疗效. 肾脏病与透析肾移植杂志, 2022, 31(1): 15-20.
26. 张洁婷, 梁玉婷, 魏爽, 等. 血液透析患者透析相关知识知晓情况及其影响因素分析. 中国血液净化, 2019, 18(11): 791-794.
27. 王婷婷, 马迎春. 维持性血液透析患者运动康复的实施及影响因素. 中国血液净化, 2019, 18(3): 204-206.
28. 胡瑞, 邱文龙, 赵喜红, 等. 从肾移植术后感染新冠肺炎谈免疫宿主低下人群的管理. 中华危重病急救医学, 2022, 34(5): 492-496.
29. Bhatt GC, Sethi SK, Mehta I, et al. Literature review of the efficacy of high-volume hemofiltration in critically ill pediatric patients. Blood Purif, 2022, 51(8): 649-659.
30. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med, 2014, 370(15): 1383-1392.
31. Choi JY, Cho SG, Jang KS, et al. Voriconazole-induced Severe Hyperkalemia Precipitated by Multiple Drug Interactions. Electrolyte Blood Press, 2020, 18(1): 10-15.
32. Dos Santos RG, Malinovski J, Scatone N, et al. MO595 frequency of intake of dietary fiber sources not associated with hyperkalemia in hemodialys patients in a multicenter study. Nephrol Dial Transpl, 2021, 36(Suppl 1): gfab089-008.
33. 姜美. 研究尿毒症患者输血发生高钾血症原因及护理. 中国现代药物应用, 2017, 11(16): 166-167.
34. 李萍, 钱巧慧, 崔丽, 等. 医联体内知识共享的范畴研究. 中国全科医学, 2018, 21(13): 1539-1545.
35. Rossignol P, Pitt B. Heart failure and chronic kidney disease patients. J Am Coll Cardiol, 2021, 78(4): 344-347.
36. 刘宏, 刘必成. 慢性肾脏病合并高钾血症: 老问题、新对策. 中华医学杂志, 2021, 101(42): 3447-3450.
37. Gaudry S, Quenot JP, Hertig A, et al. Timing of renal replacement therapy for severe acute kidney injury in critically ill patients. Am J Respir Crit Care Med, 2019, 199(9): 1066-1075.
38. Chen H, Cheng Q, Wang J, et al. Long‐term efficacy and safety of hypoxia‐inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: a meta‐analysis including 13, 146 patients. J Clin Pharm Ther, 2021, 46(4): 999-1009.
39. Brueske B, Sidhu MS, Schulman‐Marcus J, et al. Hyperkalemia is associated with increased mortality among unselected cardiac intensive care unit patients. J Am Heart Assoc, 2019, 8(7): e011814.
40. Thongprayoon C, Cheungpasitporn W, Radhakrishnan Y, et al. Association of serum potassium derangements with mortality among patients requiring continuous renal replacement therapy. Ther Apher Dial, 2022, 26(6): 1098-1105.
41. 陈洪, 周春华. 2007 年北京市新入血液透析患者病因组成分析. 中国血液净化, 2009, 8(10): 567-570.
42. Lisi F, Grande D, Parisi G, et al. Hyperkalemia is the main cause of mineralocorticoid receptor antagonists withdrawal and is associate with a worse prognosis in patients with chronic heart failure. Eur Heart J Suppl, 2019, 21(E): E230-E231.
43. Lowe KM, Cruz JB, Jones KM. Complications in patients with chronic kidney disease. Crit Care Nurs Clin North Am, 2022, 34(4): 395-407.
44. Stevens JS, Hastie JM, Spellman J, et al. Optimizing perioperative renal replacement therapy for patients undergoing cardiac surgical procedures requiring cardiopulmonary bypass. Blood Purif, 2022: 1-7.
45. Conley R, Rich RL, Montero J. Safety of a nurse-driven standardized potassium replacement protocol in critically ill patients with renal insufficiency. Crit Care Nurse, 2021, 41(2): e10-e16.

West China Medical Journal

Visualization analysis of research hotspots and development trends of hyperkalemia in hemodialysis patients

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content